Diagnosis and Management of Asthma in Older Adults Sanjay Haresh Chotirmall, MD, Michael Watts, MD, Peter Branagan, MD, Ciaran F

Total Page:16

File Type:pdf, Size:1020Kb

Diagnosis and Management of Asthma in Older Adults Sanjay Haresh Chotirmall, MD, Michael Watts, MD, Peter Branagan, MD, Ciaran F PROGRESS IN GERIATRICS Diagnosis and Management of Asthma in Older Adults Sanjay Haresh Chotirmall, MD, Michael Watts, MD, Peter Branagan, MD, Ciaran F. Donegan, MD, Allan Moore, MD, and Noel Gerard McElvaney, MD Despite comprehensive guidelines established by the Euro- from 6.5% to 17.0%.5 Death rates associated with asthma pean Global Initiative for Asthma and the U.S. National depend on patient age; in a group of patients aged 55 to 59, Asthma Education and Prevention Program on the diagno- the death rate was 2.8 per 100,000 people, whereas in sis and management of asthma, its mortality in older adults people aged 60 to 64, it was 4.2 per 100, 000.6 Diagnostic continues to rise. Diagnostic and therapeutic problems and therapeutic problems contribute to many patients being contribute to older patients being inadequately treated. The inadequately treated. Despite its importance in older pa- diagnosis of asthma rests on the history and characteristic tients, asthma is particularly difficult to diagnose in this age pulmonary function testing (PFT) with the demonstration group. Symptoms typical of asthma such as intermittent of reversible airway obstruction, but there are unique prob- wheezing, breathlessness, and cough can also indicate other lems in performing this test in older patients and in its in- respiratory problems in older patients, particularly chronic terpretation. This review aims to address the difficulties in obstructive pulmonary disease (COPD). Similarly, other performing and interpreting PFT in older patients because symptoms of asthma such as chest pain or tightness may of the effects of age-related changes in lung function on be due to nonpulmonary disease such as ischemic heart respiratory physiology. The concept of ‘‘airway remodel- disease,7 congestive cardiac failure, anemia, or pulmonary ing’’ resulting in ‘‘fixed obstructive’’ PFT and the relevance embolism. Furthermore, many older patients regard breath- of atopy in older people with asthma are assessed. There are lessness and cough as simply ‘‘signs of old age’’ and do not certain therapeutic issues unique to older patients with present to their general practitioner. Although age is asso- asthma, including the increased probability of adverse ciated with a progressive decrease in lung performance, the effects in the setting of multiple comorbidities and issues respiratory system remains capable of maintaining ade- surrounding effective drug delivery. The use of beta 2- quate gas exchange throughout life.8 Thus, an underlying agonist, anticholinergic, corticosteroid, and anti-immuno- diagnosis should always be sought when these symptoms globulin E treatments are discussed in the context of these are present. Treatment in older patients should be based on therapeutic issues. J Am Geriatr Soc 57:901–909, 2009. symptoms and the demonstration of airway obstruction. This is most commonly done by performing pulmonary Key words: asthma; diagnosis; treatment function testing (PFT), which can be difficult to interpret in older patients. This article aims to address difficulties in performing and interpreting PFT in older patients. Other issues related to diagnosis such as atopy will be discussed and several therapeutic aspects of asthma in older patients considered. This latter subject will focus on available drug he number of cases of asthma in all age groups is delivery methods and several classes of medications used in Tincreasing.1–3 Although awareness of many aspects of treatment, including their associated adverse effects. diagnosis and management of asthma has become well established, its mortality in older adults continues to rise.4 DESCRIPTION OF AGE EFFECTS ON ASTHMA Ireland, with the fourth highest prevalence rate of asthma worldwide, provides a case in point. As the population ages, Long-Standing Versus Late-Onset Asthma this problem has gained greater prominence, with current Older patients with asthma are divided into two major cat- estimated frequencies of asthma in elderly people ranging egories: those diagnosed as children who subsequently carry the diagnosis throughout life (long-standing asthma) and From the Department of Medicine, Beaumont Hospital, Dublin, Ireland, and those who develop new symptoms in their sixth decade Department of Medicine, Mid-Western Regional Hospital, Limerick, Ireland. of life (aged 65). Understandably, this latter group is Address correspondence to Dr. Sanjay Haresh Chotirmall, Respiratory challenging to recognize and accounts for the majority of Research Division, Education & Research Centre, Beaumont Hospital, undiagnosed cases. A number of studies have suggested that Dublin 9, Republic of Ireland. E-mail: [email protected] people with long-standing asthma have shorter symptom- DOI: 10.1111/j.1532-5415.2009.02216.x free periods, more hospitalizations, more emergency inter- JAGS 57:901–909, 2009 r 2009, Copyright the Authors Journal compilation r 2009, The American Geriatrics Society 0002-8614/09/$15.00 902 CHOTIRMALL ET AL. MAY 2009–VOL. 57, NO. 5 JAGS ventions, and worse lung function than those developing a mechanical disadvantage. Because the diaphragm is flat- symptoms at age 65 and older.9 In contrast, another study tened, its ability to generate negative intrathoracic pressure found no relationship between disease duration and sever- is reduced. In addition, a significant decrease in the strength ityFa finding now gaining broad acceptance,10 although some of the diaphragm in older patients has been shown.22 This definitions of ‘‘late-onset asthma’’ consider symptom onset at in combination with the anatomical changes in the chest ages as young as 30 as ‘‘late onset.’’11 The course of late-onset wall and its greater stiffness reduces the force-generating elderly asthma appears similar to that of long-standing asthma capacity of the diaphragm. In addition, nutritional status, in terms of respiratory dysfunction, with neither showing acute which is often deficient in older patients, frequently con- deterioration but gradual loss of ventilatory capacity instead. tributes to altered respiratory muscle strength.23 Normal aging is associated with a reduction in elastic Atopy in the Older Adult with Asthma recoil of the lung parenchyma. The exact underlying mech- anism for this remains unclear. It has been postulated that it Atopic (extrinsic) asthma is associated with disease pre- may be related to the spatial arrangement of the elastic fiber dominantly diagnosed in childhood. Its role in older adults network,20 rather than an actual reduction in the total con- with asthma is less well established. From the Greek atopos, tent of collagen and elastin. Thus, during expiration, there meaning ‘‘out of place,’’ it is defined as the genetic tendency is a greater tendency for small airways to collapse, with to develop classical allergic disease. It involves a capacity resultant air trapping and an increase in residual volume. to produce abnormal amounts of immunoglobulin E (IgE) The stiff, poorly compliant chest wall of older patients to environmental allergens such as grass or pollen. The causes less outward recoil, particularly marked at high lung ‘‘well documented’’ triad (asthma, eczema, and hay fever) volumes. This reduction in recoil pressure causes a reduc- causes a number of cases, although an isolated high IgE tion in vital capacity (VC); this is balanced by the increase in level against an allergen does not necessarily result in this residual volume (RV). Thus, older patients have greater ‘‘triad.’’ The role of atopy in the pathogenesis of asthma functional residual capacity (FRC). The net effect is that is undisputed, and a high serum IgE level has in previous older patients breathe at higher lung volumes than younger studies been found to be a risk factor for the development patients. This places increased elastic load on the chest wall of obstructive airway disease.12 Such a relationship is and an additional burden on the respiratory muscles, lead- independent of smoking, but synergism exists.13 Atopy ing to an increase in metabolic demand. is age-related: high in childhood, moderate in mid-life, and 14 low in older age groups. Consequently, high IgE levels at The Concept of ‘‘Airway Remodeling’’ Resulting in any age increase the probability of a diagnosis of asthma ‘‘Fixed Obstructive’’ PFTs during later life,15 although a past history of atopy repre- ‘‘Fixed obstruction’’ may be observed in the interpretation sents one of the predictors of asthma at an older age; if one of PFTs of people with long-standing asthma versus late- was at risk of being sensitized, this has probably already onset counterparts. A proposed mechanistic model is the occurred once entering the latter decades of life.16 Con- concept of ‘‘airway remodeling.’’ Years of airway inflam- versely, the Normative Aging Study showed that late-onset mation activate this process, which combines fibrinolytic cat hypersensitivity predicted asthma onset in older patients.17 mediators (including growth factors and interleukins) with Allergen sensitization in later life does therefore occur and an intricate interaction between cell membranes, airway may act as a predictor of asthma; a past history of atopy has epithelium, and glandular and vascular structures.24,25 The not consistently been shown to be the ‘‘strongest’’ predictor, resultant outcome is the development of permanent airway but is a predictor, of late-onset asthma. It is safe to state that narrowing, resulting in ‘‘fixed bronchial obstruction,’’ as atopy is important in some but not all cases
Recommended publications
  • Dosing Time Matters
    bioRxiv preprint doi: https://doi.org/10.1101/570119; this version posted March 21, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Dosing Time Matters 1 2,3 4,5,6 1* Marc D. Ruben ,​ David F. Smith ,​ Garret A. FitzGerald ,​ and John B. Hogenesch ​ ​ ​ ​ 1 Division​ of Human Genetics, Center for Chronobiology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, 240 Albert Sabin Way, Cincinnati, OH, 45229 2 Divisions​ of Pediatric Otolaryngology and Pulmonary and Sleep Medicine, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229 3 Department​ of Otolaryngology-Head and Neck Surgery, University of Cincinnati School of Medicine, 231 Albert Sabin Way, Cincinnati, OH, 45267 4 Department​ of Systems Pharmacology and Translational Therapeutics, at the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104 USA 5 Department​ of Medicine, at the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104 USA 6 ​ Institute for Translational Medicine and Therapeutics (ITMAT), at the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104 USA *Corresponding Author. Email: [email protected] Abstract Trainees in medicine are taught to diagnose and administer treatment as needed; time-of-day is rarely considered. Yet accumulating evidence shows that ~half of human genes and physiologic functions follow daily rhythms. Circadian medicine aims to incorporate knowledge of these rhythms to enhance diagnosis and treatment.
    [Show full text]
  • COVID-19 Evidence Bulletin 8
    COVID-19 Evidence Bulletin 8 Public Health England PHE International Epidemiology Daily Evidence Digest – 22nd April 2020 – 21st April 2020 – 20th April 2020 NICE COVID-19 rapid guideline: acute myocardial injury [NG171] Published 23rd April The purpose of this guideline is to help healthcare professionals who are not cardiology specialists identify and treat acute myocardial injury and its cardiac complications in adults with known or suspected COVID-19 but without known pre-existing cardiovascular disease. COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response [NG172] Published 23rd April The purpose of this guideline is to maximise the safety of children and adults who have gastrointestinal or liver conditions treated with drugs affecting the immune response during the COVID 19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources. COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community Published 3rd April, Last updated 22nd April NHS England Specialty Guides: Clinical guide for acute kidney injury in hospitalised patients with COVID-19 outside the intensive care unit during the coronavirus pandemic (22nd April - updated) Management of palliative care in hospital during the coronavirus pandemic (22nd April – updated) Department of Health and Social Care Medicines that cannot be parallel exported from the UK (22nd April) 33 medicines have been added to the parallel export list and the
    [Show full text]
  • Emea/666243/2009
    European Medicines Agency London, 29 October 2009 EMEA/666243/2009 ISSUE NUMBER: 0910 MONTHLY REPORT PHARMACOVIGILANCE WORKING PARTY (PHVWP) OCTOBER 2009 PLENARY MEETING The CHMP Pharmacovigilance Working Party (PhVWP) held its October 2009 plenary meeting on 19-21 October 2009. PhVWP DISCUSSIONS ON SAFETY CONCERNS Below is a summary of the discussions regarding non-centrally authorised medicinal products in accordance with the PhVWP publication policy (see under http://www.emea.europa.eu/htms/human/phv/reports.htm). Positions agreed by the PhVWP for non- centrally authorised products are recommendations to Member States. For safety updates concerning centrally authorised products and products subject to ongoing CHMP procedures, readers are referred to the CHMP Monthly Report (see under http://www.emea.europa.eu/pressoffice/presshome.htm). The PhVWP provides advice on these products to the Committee of Medicinal Products for Human Use (CHMP) upon its request. Antipsychotics - risk of venous thromboembolism (VTE) Identify risk factors for VTE for preventive action before and during treatment with antipsychotics The PhVWP completed their review on the risk of VTE of antipsychotics1. The review was triggered by and based on data from the UK spontaneous adverse drug reactions reporting system and the published literature. The PhVWP carefully considered the data, including the limitations of both information sources, such as the lack of randomised controlled trial data, the heterogeneity of published studies and the potential confounding factors such as sedation and weight gain, commonly present in antipsychotic users. The PhVWP concluded that an association between VTE and antipsychotics cannot be excluded. Distinguishing different risk levels between the various active substances was not possible.
    [Show full text]
  • Lamas for COPD Systematic Review
    Comparative safety and effectiveness of inhaled long -acting agents (corticosteroids, beta agonists, anticholinergics) for chronic obstructive pulmonary disease Comprehensive Research Plan: Systematic Review Unit April 4th, 2014 Andrea C. Tricco, PhD1 and Sharon E. Straus, MD, MSc1,2 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca [email protected] Background Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation in the lungs [1]. COPD is commonly assessed by clinical examination and spirometry. Important indicators considered in the diagnosis of COPD include age over 40 years and any of the following: 1) progressive and persistent dyspnea that worsens with exercise, 2) chronic cough, 3) chronic sputum production, 4) history of exposure to smoke from tobacco or cooking, occupational dusts and chemicals, and 5) family history of COPD [1]. COPD causes significant burden of illness, reduced quality of life, and premature death [2]. Symptoms include chronic cough, sputum production, and dyspnea [3]. The global prevalence of COPD has been estimated at 7.6% using data from a systematic review including 28 countries [4]. However, this is likely a conservative estimate, due to under-reporting and under-diagnosis. The prevalence and burden of COPD is rising due the greater proportion of elderly people in the population [1]. It is estimated that COPD will be the third-leading cause of death by 2020 [5]. The treatment of COPD usually involves reducing exposure (e.g., smoking cessation, occupation modifications), increasing exercise, and implementing appropriate pharmacologic therapy [1]. The most common drug classes are beta2-agonists, anticholinergics, and methylxanthines. Inhaled corticosteroids (ICS) and systemic corticosteroids are often useful for acute exacerbations.
    [Show full text]
  • 100 Storage Condition=50 C/Ambrh
    USOO595.5058A United States Patent (19) 11 Patent Number: S.9SS,0589 9 Jager et al. (45) Date of Patent: Sep. 21,9 1999 54). STABILIZED MEDICINAL AEROSOL 56) References Cited SOLUTION FORMULATIONS CONTAINING U.S. PATENT DOCUMENTS IPRATROPIUM BROMIDE a 5,118,494 6/1992 Schultz et al. ............................ 424/45 75 Inventors: Paul Donald Jager, Waterbury; Mark 5,190,029 3/1993 Byron et al. ... ... 128/200.14 James Kontny, New Milford, both of 5,225,183 7/1993 Purewal et al. ........................... 424/45 Conn.; Jurgen Hubert Nagel 5.439,670 8/1995 Purewal et al. ... 424/45 Ingelheim/Rhein, Germany s 5,605,674 2/1997 Purewal et al. ........................... 424/45 FOREIGN PATENT DOCUMENTS 73 Assignee: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, 0372 777 6/1990 European Pat. Off.. Conn. Primary Examiner Raj Bawa Attorney, Agent, or Firm Morgan & Finnegan, LLP 21 Appl.pp No.: 08/843,180 57 ABSTRACT 22 Filed: Apr. 14, 1997 Stabilized medicinal aeroSol Solution formulations compris O O ing medicaments that degrade or decompose by interaction Related U.S. Application Data with solvents or water, an HFC propellant, a cosolvent and an acid are described. Further, Specific medicinal aeroSol 63 Staggypt.NE "A iGs Solution formulations comprising ipratropium bromide or No. 08/153.549, Nov. 22, 1993, abandoned E. is a fenoterol, ethyl alcohol, 1,1,1,2-tetrafluoroethane or 1,1,1, continuation-in-part of application No. 07/987,852, Dec. 9, 2,3,3,3-heptafluoropropane, and either an inorganic acid or 1992, abandoned. an organic acid are described. The acids are present in 51 Int.
    [Show full text]
  • Pharmacology and Therapeutics of Bronchodilators
    1521-0081/12/6403-450–504$25.00 PHARMACOLOGICAL REVIEWS Vol. 64, No. 3 Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics 4580/3762238 Pharmacol Rev 64:450–504, 2012 ASSOCIATE EDITOR: DAVID R. SIBLEY Pharmacology and Therapeutics of Bronchodilators Mario Cazzola, Clive P. Page, Luigino Calzetta, and M. Gabriella Matera Department of Internal Medicine, Unit of Respiratory Clinical Pharmacology, University of Rome ‘Tor Vergata,’ Rome, Italy (M.C., L.C.); Department of Pulmonary Rehabilitation, San Raffaele Pisana Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy (M.C., L.C.); Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, UK (C.P.P., L.C.); and Department of Experimental Medicine, Unit of Pharmacology, Second University of Naples, Naples, Italy (M.G.M.) Abstract............................................................................... 451 I. Introduction: the physiological rationale for using bronchodilators .......................... 452 II. ␤-Adrenergic receptor agonists .......................................................... 455 A. A history of the development of ␤-adrenergic receptor agonists: from nonselective ␤ Downloaded from adrenergic receptor agonists to 2-adrenergic receptor-selective drugs.................... 455 ␤ B. Short-acting 2-adrenergic receptor agonists........................................... 457 1. Albuterol........................................................................ 457
    [Show full text]
  • Bnf Chapter 3: Respiratory
    BNF CHAPTER 3: RESPIRATORY Information resources: ● If an inhaler device is changed then patients must be assessed to ensure inhaler technique is adequate Respiratory Futures Consider issuing a Steroid warning card to patients prescribed high dose inhaled steroids Asthma guidelines NICE guideline [NG80] Asthma: diagnosis, monitoring and chronic asthma management NICE guidance TA 138 Asthma - inhaled corticosteroids for the treatment of chronic asthma in adults and children aged 12 years and over. https://www.sign.ac.uk/assets/sign153.pdf SIGN 153: British guideline on the management of asthma Global Initiative for Asthma 2018. GINA Report, Global Strategy for Asthma Management and Prevention. West Cheshire local guidelines COPD guidelines: NICE [NG115] COPD in over 16s diagnosis and management. NICE guideline Dec 18 [NG115] GOLD : Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease 2018 Report West Cheshire local guidelines Abbreviations used: MDI: metered dose inhaler DPI: dry powder inhaler SABA: short acting beta agonist LABA: long acting beta agonist SAMA: short acting muscarinic antagonist LAMA: long acting muscarinic antagonist ICS: inhaled corticosteroid LTRA: leukotriene receptor antagonist PDE4: phosphodiesterase-4 enzyme inhibitor Joint Formulary – Respiratory Approved by Area Prescribing Committee: n/a Review by: July 2021 3.1 BRONCHODILATORS 3.1.1.1 SELECTIVE BETA2-AGONISTS Short acting Beta2 Agonist (SABA) Salbutamol 100 micrograms/metered inhalation MDI 100/200
    [Show full text]
  • Dry Powder Inhalers Comprising a Carrier Other Than Lactose
    (19) TZZ Z T (11) EP 2 682 097 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.01.2014 Bulletin 2014/02 A61K 9/00 (2006.01) A61K 9/14 (2006.01) A61K 31/40 (2006.01) A61K 31/439 (2006.01) (2006.01) (21) Application number: 13175077.0 A61K 31/4704 (22) Date of filing: 04.07.2013 (84) Designated Contracting States: • Türkyilmaz, Ali AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 34460 Istanbul (TR) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Mutlu, Onur PL PT RO RS SE SI SK SM TR 34460 Istanbul (TR) Designated Extension States: BA ME (74) Representative: Sevinç, Erkan Istanbul Patent & Trademark (30) Priority: 05.07.2012 TR 201207842 Consultancy Ltd. Plaza 33, Buyukdere Cad. No: 33/16 (71) Applicant: Arven Ilac Sanayi Ve Ticaret A.S. Sisli Istanbul 34460 (TR) 34381 Istanbul (TR) (72) Inventors: • Cifter, Ümit 34460 Istanbul (TR) (54) Dry Powder Inhalers Comprising A Carrier Other Than Lactose (57) This invention relates to novel pharmaceutical other obstructive airways diseases. In addition, the compositions for inhalation comprising separately, se- present invention relates to novel pharmaceutical com- quentially or together, drugs having amine in the form of position for inhalation based on combinations of long act- a dry powder in admixture with a pharmaceutically ac- ing muscarinic antagonists, long acting beta agonists, ceptable carrier, other than lactose, and its use in the short acting beta-2 agonists, corticosteroids or a combi- treatment of respiratory condition selected from asthma nation of two or more of them.
    [Show full text]
  • Management of Asthma in Athletes Michael G
    Journal of Athletic Training 2005;40(3):224±245 q by the National Athletic Trainers' Association, Inc www.journalofathletictraining.org National Athletic Trainers' Association Position Statement: Management of Asthma in Athletes Michael G. Miller*; John M. Weiler²; Robert Baker³; James Collins§; Gilbert D'Alonzo\ *Western Michigan University, Kalamazoo, MI; ²University of Iowa and CompleWare, Iowa City, IA; ³Michigan State University Kalamazoo Center for Medical Studies, Kalamazoo, MI; §San Diego Chargers, San Diego, CA; \Temple University School of Medicine, Philadelphia, PA Michael G. Miller, EdD, ATC, CSCS; John M. Weiler, MD; Robert Baker, MD, PhD, ATC; James Collins, ATC; and Gilbert D'Alonzo, DO, contributed to conception and design; acquisition and analysis and interpretation of the data; and drafting, critical revision, and ®nal approval of the article. Address correspondence to National Athletic Trainers' Association, Communications Department, 2952 Stemmons Freeway, Dallas, TX 75247. Objective: To present guidelines for the recognition, prophy- in supervising therapies to prevent and control asthma symp- laxis, and management of asthma that lead to improvement in toms. It is also important for the athletic trainer to recognize the quality of care certi®ed athletic trainers and other heath care when asthma is not the underlying cause for respiratory dif®- providers can offer to athletes with asthma, especially exercise- culties, so that the athlete can be evaluated and treated prop- induced asthma. erly. Background: Many athletes have dif®culty breathing during Recommendations: The recommendations contained in this or after athletic events and practices. Although a wide variety position statement describe a structured approach for the di- of conditions can predispose an athlete to breathing dif®culties, agnosis and management of asthma in an exercising popula- tion.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0302147 A1 HARTMAN Et Al
    US 20140302147A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0302147 A1 HARTMAN et al. (43) Pub. Date: Oct. 9, 2014 (54) RESPRABLEAGGLOMERATES OF POROUS Publication Classification CARRIER PARTICLES AND MICRONIZED DRUG (51) Int. Cl. A619/16 (2006.01) (71) Applicants: Michael HARTMAN, Millbrae, CA A619/00 (2006.01) (US); Thomas ETARARA, A613 L/40 (2006.01) Burlingame, CA (US); Patrick TEUNG, A613 L/4704 (2006.01) Sunnyvale, CA (US); Jeffry G WEERS, A613 L/58 (2006.01) Belmont, CA (US) (52) U.S. Cl. CPC ........... A61 K9/1617 (2013.01); A61 K3I/4704 (72) Inventors: Michael HARTMAN, Millbrae, CA (2013.01); A61 K3I/58 (2013.01); A61K 31/40 (US); Thomas ETARARA, (2013.01); A61 K9/1682 (2013.01); A61 K Burlingame, CA (US); Patrick TEUNG, 9/0075 (2013.01) Sunnyvale, CA (US); Jeffry G WEERS, USPC ............................ 424/489: 514/312: 514/171 Belmont, CA (US) (57) ABSTRACT Embodiments of the present invention provide a dry powder Assignee: composition comprising porous carrier particles associated (73) NOVARTIS AG, Basel (CH) with one, two, three or more micronized drugs or APIs wherein an ordered mixture between the micronized drug or (21) Appl. No.: 14/202,262 drugs and the carrier particle results, such that the micronized drug or drugs adhere strongly to the carrier particles forming a stable ordered mixture of respirable agglomerates. Embodi (22) Filed: Mar 10, 2014 ments of the present invention further comprise a spray-dry ing process to create the respirable agglomerates. Embodi ments of the present invention further relate to the use of the Related U.S.
    [Show full text]
  • Supplementary Material A: RECORD Statement
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open Supplementary Material A: RECORD Statement The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data. Item STROBE items Location in RECORD items Location in manuscript where No. manuscript where items are reported items are reported Title and abstract 1 (a) Indicate the Page 1 in title and RECORD 1.1: The type of data 1.1 Page 1 in the abstract. study’s design with abstract used should be specified in the a commonly used title or abstract. When possible, term in the title or the name of the databases used the abstract (b) should be included. Provide in the 1.2 Page 1 in the abstract. abstract an RECORD 1.2: If applicable, informative and the geographic region and balanced summary timeframe within which the of what was done study took place should be and what was found reported in the title or abstract. 1.3 Page 1 – data were linked in a system wide dataset. RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract. Introduction Background 2 Explain the Page 3 under rationale scientific Introduction background and rationale for the investigation being reported Objectives 3 State specific Page 3 at the bottom objectives, including of the page. any prespecified hypotheses Methods Study Design 4 Present key elements Page 4 under 2.1 Data, of study design early application and in the paper setting.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]